BACKGROUNO: Nonadherence to statins limits the benefits of this common drug class . Individual studies assessing predictors of nonadherence have produced inconsistent results. OBJECTIVE: To identify reliable predictors of nonadherence to statins through systematic review and meta-analysis.
S tatins are highly effective medications for avoiding cardiovascular events.P Accordingly, their use has become widespread and continues to increase,'Despite a favorable adverse effect profile in a majority of patients'and evidence that low adherence to statins is linked withworse outcomes."? numerous studies have documented high rates of nonadherence to these drugs. 8 ,9 Identifying patients with lowadherence is a challenge. Using clinical judgment alone, physicians are poorat identifying which patients have problems with adherence.P" Much of the research on statin adherence is derived from largeinsurance and pharmacy databases. These studies have generated a list of potential predictors of nonadherence. Previous reviews of these predictors have observed a wide variation in the types of predictors considered.tz,13 Moreover, these reviews have qualitatively concluded that there are no consistent sociodemographic or medical predictors of nonadherence,"
The variability in the identification of predictors of nonadherence may stem from the diversity of studydesigns, populations, and measurement methodologies, as well as secular trends in statin use. Previous reviews haveelected to systematically evaluate adherence predictors, without performing a quantitative pooling of data. n,t3 Identification of consistentpredictors of statin adherence across populations and studies may Author information provided at end of text.
providetargets for the development of effectiveinterventions to improve statin adherence. To expand our understanding of factors associated withnonadherence to statins, we performed a review of the literature and quantitative pooling of prior studies, Weexamined observational studies to assess the relationship between individual level characteristics and statin nonadherence.
Methods

STUDY SELECTION
Eligible study designs included prospective or retrospective observational cohorts in which adherence to statins was evaluated as an outcome measure. Articles were considered only if they were available in full-text and English and ifthey included community-dwelling adults 18 years of age and older. Eligible studies measured adherence using either a validated self-report scale or objective measures including medication refill data, pill counts, or electronic medication monitoring. To be included, studies also had to have a description of the study design and the analysis had to report on at least 2 predictors of adherence to statins in a multivariable analysis with relative risks. As per prespecified criteria, studies with fewer than 50 participants were excluded because accurate characterization of the predictive strength of multiple independent features would be weakened (ie, potential for "over fitting" of the models). SEARCHING able from the abstract, the full text of the article was obtained. After obtaining full text of these studies, the same reviewers independently assessed eligibility, using a predefined protocol."
Several additional quality measures were incorporated at this stage. Studies were included only if they measured adherence using either a validated self-report scale or an objective measure of adherence (medication refill data, pill counts, or electronic medication monitoring). A number of sociodemographic characteristics, comorbid medical conditions, and regimen complexity qualities have been known to affect statin adherence," Accordingly, as a second quality filter, we included only studies that adjusted for at least 1 characteristic in their analysis of the association between candidate predictors and adherence to statins. Finally, as we were interested in deriving a quantitative estimate of the strength of candidate predictors of statin adherence, we excluded articles in which relative risks and a measure of its variance were not reported. The 2 authors met again after selecting articles based on these quality measures to discuss discrepancies and achieve consensus for final eligibility in this meta-analysis.
DATA SYNTHESIS
DATA EXTRACTION
Data from the identified studies were abstracted independently using a standardized form. Data abstractors (DMM, IK) collected information about the country of origin, study populations, sample size, method of adherence measurement, mean adherence, and predictors of adherence. When more than 1 adherence measurement technique was used, data on all measures used were extracted separately. For studies with incomplete quantitative information available on predictors, attempts were made to obtain data from study authors.
Studies were grouped based on the type of adherence measure utilized (validated self-report scale, pharmacy or insurance claims refill data, pill counts, or electronic medication monitoring). Those relying on pharmacy or insurance claims refill data calculated adherence using 2 types of measures. The first type is usually referred to as the proportion of days, covered (PDC) and is calculated as the sum of the days' supply obtained between the first and last pharmacy fill dates divided by the total number of days in this time period," This measure is dichotomized and individuals are categorized into adherent and nonadherent groups using a set threshold for PDC (usually 80%). The second adherence measure categorizes patients as adherent or nonadherent depending on whether individuals discontinued their medication over a set time period (usually 1 or 2 years). 
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Two investigators (DMM, IK), working independently, reviewed all of the abstracts and obtained the full text of potentially relevant articles. After applying the study selection criteria noted above, the 2 reviewers met to achieve consensus on candidate abstracts for full-text, methodological review. In cases when limited information was avail-This study was performed as part of a larger systematic review of predictors of adherence to oral cardiovascular and diabetic medications. All methods were informed by the meta-analysis of observational studies in epidemiology criteria." Potentially relevant articles were identified by searching publicly available computerized databases with the assistance of a trained medical librarian (LF). The search included all articles published from inception through February 2009 from MEDLINE, Cochrane Central Register of Controlled Trials, Database of Abstracts of Reviews of Effects, National Health Service Economic and Evaluation Database, Health Technology Assessment Database, EMBASE, and PsycINFO. All relevant subject heading and free-text terms used to represent cardiovascular disease or diabetes were combined with terms for adherence or compliance (Appendix I). For this substudy, terms for both the generic class of drug (statins) and the individual names, generic and proprietary, were included. Due to the very large volume of literature on this topic, a set of methodological terms (or filter) was applied to the search strategies of the larger databases (MEDLINE, EMBASE, and PsycINFO) to capture relevant study designs.
Predictors were selected for quantitative pooling if 4 or more articles employing similar adherence measurement techniques were available. Several studies presented data only in subgroups and performed all analyses as distinct populations (eg, by sex, age, history of cardiovascular disease [CVDDP-19 As such, thesedata were treatedas multiple studies within the same article.Individualestimatesof relative risk were pooled usingrandom-effects meta-analysis with inverse variance weighting" in Stata, version 10 (College Station,TX). When publications displayed results for distinct subgroups (eg, men and women), the subgroups were includedas separateterms in the meta-analysis. Pooled estimates were calculated separately for PDC and discontinuation, as well as for an overall estimatecombining the 2 outcomes. The P statistic was used to estimate the percentage of variability across studies that is attributable to heterogeneity" and tested for deviation from zero. Quantitative variables were typically reported in ordinal groupedformat. If the raw data suggested a monotonic trend, we pooled relative risks, comparing the highest to the lowest group (eg, for income). Where there was no such monotonic relationship and no clear parametric response relationship, we plotted individual studies rather than pooling (eg, for age). To test for potential sources of heterogeneity between studies, subgroup analyses were performed on each of the final predictors by countryof origin (North America vs other) and by the median sample size (n = 20,(00), year of study (2005) ,and duration of follow-up(5 years).
Results
SEARCH RESULTS
A comprehensive search was performed in March 2009 and yielded a totalof 11 ,461 unique articles. Figure 1 shows the flowof literature intothe systematic review. A totalof 22 articles metthe final inclusion criteria for the study of predictors of adherence to statins ( Table 1 ).Only 1 article reported statinadherence usinga validated self-report scale," and no articles reported statin adherence using eitherelectronic medication monitoring or pillcounts. As a result, onlystudies usingpharmacy and insurance database refill rates wereincluded for meta-analysis. As depicted in Figures 2-6, the pooled estimates forthe2 outcomes (PDCanddiscontinuation) were similar, justifying use of an overall pooled estimate as an appropriate measure of association.
PREDICTORS
Reviewed articles considereda broad range of possible predictors including demographics (race,sex, income,ethnicity), psychiatric illness (depression),cognitive impair-ment (dementia),physician factors (communication skills, racial concordance),health beliefs of patients,complexity of medication regimen (numberof medications, dosing frequency), severityof disease, adverseeffects,and systemic barriers (cost, transitions in care from outpatient to inpatient, restricted formularies). For each risk factor, the percentage of variability due to between-study heterogeneity was large and, except in the case of income, significantly different from zero (p < 0.05).
Age
Age was a statistically significant predictor of adherence in all studies. However, the relationship was not monotonic. The youngest participants (usually <50 years)were significantly more likely to have loweradherence (PDC <80%)or to havediscontinued their statin compared to "middle-aged" adults (usually 50-65 years). However, olderadults (usuallỹ 70 years) alsodisplayed loweradherence and increased discontinuation compared to middle-aged adults. For example, in the study by Benneretal.,nusing adults aged 18-34 as the reference, a Ll-shaped relationship was observed with an oddsfor nonadherence of 0.68 (95%CI 056 to 0.85)among 35-44 yearolds, 0.41 (95% CI 0.34 to 050) among45-54 yearolds,O.34 (95%CI028 toOAl) among subjects 55-64 years old, 0.44 (95% CI 0.36 to 0.53) among those 65-74 yearsold, and 0.46 (95%CI 0.38 to 0.57) amongthose~75 years old. Figure7 demonstrates the U-shaped relationship among 4 studiesthat examinedage as a predictorand used PDCas the adherence measure (theother7 useddiscontinuation). In total, 10 of the 11 studies that examined age as a multi-level predictor of statin adherence 8 ,18,21-28 were consistent withthe aforementioned If-shapedrelationship, while 1 study" showed a more monotonic improvementof adher- 
Sex
Eighteen studies examined sex as a predictor of adherence, and the majority of these showed that women were less likelyto be adherent (Figure2). 5, 8, 17, 22, 23, 25, 26, [30] [31] [32] [33] The relative risk for low adherence, comparing women to men, via PDC, discontinuation, and overall were 1.07 (95% CI 1.02to 1.12), 1.07 (95% CI 1.03to 1.12), and 1.07 (95% CI 1.04to 1.11), respectively. 9 studies (Figure4). 8, 9, 22, 26, 27, 29, 30, 33, 34 Overall,patients with a history of CVD were more likely to be adherent (odds of nonadherence 0.68; 95% CI 0.68 to 0.71). Similarly, those with a history of hypertension were more likely to be adherent in 12 studies, 8, 9, 17, 22, 26, 27, 29, 31, 32, 34, 35 with a trend toward better adherence in the remaining studies ( Figure 5 ). 18, 33 People with diabetes were also more likely to be adherent in 7 of 13 studies. 8,9,17,29,3I,34 Diabetes was associated with a trend toward worse adherence in just 1 study" and had equivocal results in the remaining 5 studies ( Figure  6 ),18,32,33
Income
Higher income was significantly associated with adherence assessed by PDC and discontinuation in 5 studies,17,19,22,29 with equivocal results in 4 studies ( Figure  3 ).5,28,31 Overall, patients with higher income were more likely to be adherent(odds of nonadherence 0.85; 95% CI 0.78 to 0.91).
Comorbiditles
A history of myocardial infarction (MI) or CVD equivalent(MI or stroke) was associated with higheradherence in
Regimen Complexity
Regimen complexity was'examined in 8 studies as a possible predictor of adherence to statins. 8, 9, 18, 22, 25, 31, 34 Overall, there was no clear pattern of association between the total number of medications people were prescribed and their adherence to statins. There was a relatively strong relationship between increasingnumber of noncardiovascular medications and low statin adherence. In contrast, an increasing number of cardiovascular medications was associated with higher statin adherence in 1 study," Subtotal O-squared =68.7%,p =0.(01) Figure 2 . Forest plot of relative risks for nonadherence comparingwomento men. The center of each box is plotted at the relative risk for that study;
the boxes are drawn in proportionto the amountof statisticalinformationprovidedby that study, and the lines go out to the 95% confidence limits.
Other Predictors
There was no clear relationship between the number of health-care provider visits and adherence. Increasing number of visits was associated with better adherence in 3 of 12 studies examining this relationship'I-" and a trend toward better adherence in 1 other study," However, it was associated with worse adherence in 2 studies,30,31 a trend toward worse adherence in I study," and an equivocal relationship in 5 studies. 9 .l 8, 33.l4 Several other variables were recorded in too few studies for quantitative pooling but suggested trends in their relationships with nonadherence. For example, only 3 eligible articles examined race/ethnicity as a predictor of statin adherence and demonstrated that minorities were less likely to be adherent than were white patients. 9, 21, 30 Similarly, I of 2 articles found that people with depression were less likely to be adherent'r" In I article, first-time statin users were less likely to be adherent as compared to experienced statin users," In 3 studies, people who underwent lipid testing had better adherence. 22,30,32 In 3 out of 3 studies, higher out-ofpocket costs were associated with lower statin adherence .29,30,36
Predictors ofNonadherenceto Statins
SUBGROUPANALYSIS
Grouping articles according to country of participants, years patients were studied, and duration of follow-up did not substantially alter the heterogeneity between studies. The only significant reduction in heterogeneity occurred for the history of an MI or CVD equivalent predictor in studies with <20,000 participants (p < 0.000 I , J2 0%).
Discussion
These data demonstrate that several sociodemographic, medical history, and health-care utilization variables are reliably associated with adherence to statins. Female sex was significantly associated with increased nonadherence and qualitative review suggested that ethnic groups other than white were also more likely to be nonadherent. Age appeared to have a V-shape relationship with adherence with the relatively young adults (<50 years) and those ?:-70 years of age demonstrating higher rates of nonadherence compared to middle-aged adults. A history of comorbid diabetes, hypertension, or cardiovascular disease was as- sociated with better adherence, as was higher income and increased testing of lipid levels. Other commonly studied variables, including the frequency of medical visits and increased complexity of noncardiovascular drug regimens, demonstrated no clear relationship to statin adherence.
There are many possible explanations for the observed relationships. Women are known to access medical care more frequently and to be more attentive to their health." Their more careful approach to health may lead to increased doubts regarding the need for statins or more concerns about their potential adverse effects. 21 ,38 On the other hand, minority ethnic groups are known to have less access to care, which could lead to lower oversight of their care, and in turn, lower adherence." The trend toward an association between more frequent lipid testing with better adherence suggests that access to care could explain the association between race/ethnic group and statin adherence.
Higher rates of adherence among adults with higher income and the trend toward lower adherence with increasing out-of-pocket costs have been observed across many drug classes and appear to have a clear dose-response relationship." The relationship is robust regardless of the type of cost (eg, co-pay, coinsurance). Accordingly, the low outof-pocket cost of medications for veterans may partially explain the higher rates of adherence to statins observed in Veterans Administration populations." The importance of financial resources as a barrier to achieving high rates of adherence was recently highlighted in the development of a new rapid adherence screener that identified financial barriers as 1 of 3 critical barriers to chronic disease medication adherence,"
Psychological theories, such as the health belief model, suggest that perceived risk of a disease affects behaviors." Hence, the observed Ll-shaped relationship for age in which younger adults are less adherent may be explained by the fact that younger individuals are less likely to perceive themselves as being at risk for heart disease. The relationship between lower perceived heart disease risk and lower statin adherence has been noted in other settings," The observed association between a history of MI or CVD equivalent, diabetes, and hypertension with higher adherence further supports the connection between perceived risk of heart disease and statin adherence. The higher rate of adherence among people taking more cardiovascular medications observed in one study also supports this relationship between perceived risk and adherence. Although 
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Subtotal~-squared =96.3%, P < 0.001) Overall~·squared = 96.2%, p < 0.001) -- older adults should perceive a higher CVD risk, low statin adherence in this group is likely a product of complex regimens, sensitivity to medication costs, and increasing prevalence of impaired cognition and health literacy.12,43 Similarly, lower adherence among those taking more noncardiovascular medications may be a result of increased complexity of medication regimens.
In contrast to the large number of articles reviewed here that considered predictors of medication adherence using medication refill databases, there was a paucity of articles meeting our inclusion criteria that considered predictors of medication adherence using validated self-report scales. This has limited the conclusions that can be made regarding how more detailed patient-level predictors such as health beliefs influence medication adherence." Future studies need to more carefully explore how individual health beliefs and expectations shape adherence to statins and other CVD medications.
Prior reviews of adherence predictors have observed inconsistent results. 12 • 13 ,44 In the comprehensive review of predictors of adherence to any medication, DiMatteo examined the effects of patient demographics on adherence among 569 studies ranging from HIV to cancer studies." It was found that demographic variables had small effects on adherence, in part due to the disparate sample characteristics and measurement variables. This diversity in adherence studies led Vik and colleagues to limit their work to a systematic review of medication adherence correlates among older adults." They reported polypharmacy and poor patient-clinician relationships as possible predictors of poor medication adherence and concluded that sociodemographics had negligible impact and there was "little consensus regarding other determinants of nonadherence." We chose to focus our meta-analysis on statin adherence studies using standardized adherence measures (refill rates from pharmacy and insurance claims databases) to alleviate the issues of excessive heterogeneity found in the prior reviews. This approach allowed us to reduce the variability and quantify the relationship between the candidate predictors and statin adherence. We suspect this is a critical reason for our ability to observe the reported predictive relationships.
Our study should be interpreted in the context of several limitations. We narrowed our study question to statin adherence studies with validated measurements of adherence. This was done in an attempt to identify a homogenous group of studies to evaluate. However, this did not eliminate significant heterogeneity between the studies and 
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The Annals ofPharmacotherapy • 2010September. volume 44 • 1417 studies of mixed quality and sizes were combined. Our subgroup analyses did not find differences to help account for some of the observed heterogeneity. This heterogeneity may beexplained by the high level of precision of the relative risks reported by individual studies. The high precision is reflective of the large data sets typical of the majority of the studies pooled in the meta-analysis. The comparison of high and low values for several predictors also contributes heterogeneity due to the different thresholds set in the individual studies.We also pooled resultsfrom studies drawn from over 10 years of research (no relevant articles were found prior to 1998).Trends in medication taking-related behaviors may have changedsignificantly over this period and this may contribute to variability in our estimates. Each study used various levels of adjustment for confounders, which also contributesto the heterogeneity. Althoughour use of a randomeffects modelaccounts for heterogeneity between studies, our estimates of the odds of nonadherence for predictors are likely conservative and may still be affected by uncontroIled confounders. In summary, our systematic review identified sociodemographic,medical,and health-care utilization characteristics thatare associated withstatin adherence. Several of the identified predictors arelikely notunique to statins"andmayrepresenta core set of easilyobtainable variables that should be used to identify individuals and populations at risk for poor adherence to othercardiovascular (eg,antihypertensives, aspirin,antidiabetics) andpotentially noncardiovascular (eg,osteoporosis) medications. Additional predictors likelyexist, and additional high-quality research of adherence predictors usinggold-standard adherence measurement techniques and considering patient-level characteristics is needed.
The current predictors of adherence should be used to identify high-risk populations for targeted counseling and to design adherence interventions aimed at these high-risk groups.Particular attention shouldbe paid to youngerindividualsand those who are takingstatinsas part of primary prevention, as these groups hadthehighest rates of nonadherence. Cliriicians may consideremphasizing nonpharmacologic approaches in addition to statinsfor reducingcholesterollevelsin these patient populations withlowerCVD risk. Future research should attempt to clarify the underlying mechanisms for differences in adherence identified by these characteristics. incumplimiento 1.07 (95%CI 1.04Y1.11)] y que aqueUos con ingresos mas altos [probabilidad de incumplimiento 1.1 8 (95%CI 1.1 0 Y1.28)] respectivamente. Un historial de enfennedadcardiovascular predijo un mejorcumplimiento con lasestatinas [probabilidad de incumplimiento 0.68 (95%CI 0.66 Y0.78)].De igual manera, un diagn6stico de hipertensi6n 0 diabetes estuvoasociado con un mejorcumplimiento. Aunquehubomuypocosestudios para una agrupaci6n cuantitativa, un aumentoen los estudios de lfpidos y gastosde bolsillo mas bajos parecieron estarasociados con un mejorcumplimiento. Hubouna heterogeneidad sustancial (P alcance 68.7-96.3%)entrelos estudios a travesde los factores. CONCLUSIONES: Varias caracteristicas sociodemograficas, medicas y de utilizaci6n de los servicios de saludestan asociadas con el incumplimiento del tratamiento conestatinas. Estosfactores pueden ser gufasutilesparael enfoque de intervenciones que ayuden al cumplimiento del tratamiento con estatinas. 
